CNS
Specific Antisense Oligonucleotide Market, by Drug (Approved and Pipeline),
by Indication (Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy,
Spinal Muscular Atrophy, and Huntington’s Disease), by Distribution Channel
(Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North
America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was
valued at US$ 883.7 million in 2017, and is projected to exhibit a CAGR of
24.9% over the forecast period (2018 – 2026).
Strong research and development
by market players is expected to augment the market growth Key players in the
market are focused on research and development to address the critical unmet
needs of patients suffering from neurodegenerative disorder and cancer. For
instance, as of 2018, there are around 8 novel research candidate in
development stage targeting CNS disease, which are rare in nature. Many of them
are in phase I of development. Company such as Ionis has 28 ongoing clinical
trials, 5 of which are targeted at CNS disorders. Moreover, approval of novel
antisense oligonucleotide is expected to boost the market growth. For instance,
in October 2018, Alnylam Pharmaceuticals, Inc. received the U.S. Food and Drug
Administration (FDA) approval for its ONPATTRO (patisiran) lipid complex
injection, for the treatment of the polyneuropathy of hereditary
transthyretin-mediated (hATTR) amyloidosis in adults.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2477
Browse 38 Market Data Tables and
32 Figures spread through 206 Pages and in-depth TOC on ‘CNS Specific Antisense
Oligonucleotide Market’- Global Forecast to 2026, by Drug (Approved and
Pipeline), by Indication (Hereditary transthyretin amyloidosis (hATTR)/
Polyneuropathy, Spinal Muscular Atrophy, and
Huntington’s Disease), by Distribution Channel (Hospital Pharmacy,
Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America,
Europe, Asia Pacific, Middle East, and Africa)
Key players in the market are
focused on adopting strategies such as mergers and acquisitions to enhance
their product portfolio. For instance, in August 2018, Alnylam Pharmaceuticals,
Inc. partnered with Orsini Healthcare, a specialty pharmacy as distributor of ONPATTRO
(patisiran) lipid complex injection.
Key Takeaways of the CNS Specific
Antisense Oligonucleotide Market:
The global CNS specific antisense
oligonucleotide market is expected to exhibit a CAGR of 24.9% over the forecast
period, owing to increasing prevalence of neurodegenerative diseases.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/cns-specific-antisense-oligonucleotide-market-2477
Among drug type, the approved
segment held a dominant position in the CNS specific oligonucleotide market in
2018, owing to commercialization of approved drugs in market.
Among indication type, hereditary
transthyretin amyloidosis (hATTR)/ Polyneuropathy segment held a dominant
position in the CNS specific oligonucleotide market in 2018, as majority of the
drugs are approved for this indication.
Among distribution channel,
hospital pharmacy segment held a dominant position in the CNS specific
oligonucleotide market in 2018, as majority of rare and neurodegenerative cases
are registered in hospitals.
Key players operating in the
global CNS specific oligonucleotide market include Alnylam Pharmaceuticals
Inc., Sarepta Therapeutics Inc., Biogen Inc., Ionis Pharmaceuticals Inc., Wave
Life Sciences Ltd., Stroke Therapeutic Inc., Dynacure, ProQR Therapeutics N.V.,
and Q-STATE BIOSCIENCES, INC.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2477
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S. Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment